Raritan, NJ, United States of America

Jin Zhu

USPTO Granted Patents = 4 

Average Co-Inventor Count = 15.1

ph-index = 3

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 2010-2014

Loading Chart...
4 patents (USPTO):

Title: Jin Zhu: Innovator in Antiviral Treatments

Introduction

Jin Zhu, based in Raritan, NJ, has made significant contributions to the field of virology through his inventive prowess. With a total of four patents to his name, he has developed novel compounds and methods that aim to combat viral infections effectively.

Latest Patents

One of Jin Zhu's notable patents includes a new class of indole derivatives designed for antiviral treatment. This invention focuses on compounds and their pharmaceutical compositions, which have demonstrated the ability to treat viral infections by modulating viral replication. Another significant patent involves methods for treating hepatitis C, which encompasses compounds, pharmaceutical compositions, and their applications in addressing viral infections and affecting viral IRES activity.

Career Highlights

Currently, Jin Zhu is a valuable member of PTC Therapeutics, Inc., where he engages in innovative research aimed at developing life-saving therapies. His work emphasizes the importance of finding effective treatments for viral pathogens, showcasing his commitment to enhancing global health.

Collaborations

Throughout his career, Jin has collaborated with esteemed colleagues, including Gary Mitchell Karp and James Jan Takasugi. These partnerships have enhanced his research efforts and contributed to the development of impactful pharmaceutical solutions.

Conclusion

Jin Zhu's innovative contributions to antiviral treatments demonstrate his dedication to advancing medical science. With a strong patent portfolio and collaborative spirit, he continues to be a driving force in the search for effective therapies against viral infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…